Antiviral efficacy of EICAR against canine distemper virus (CDV) in vitro.

Canine distemper virus (CDV) is a highly contagious pathogen of carnivores. In dogs, the disease is characterized by high lethality rates and no specific antiviral therapy is available. In this study, the aim was to verify the in vitro antiviral activity of the 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide (EICAR) and to compare it with the 1-(β-D-ribofuranosil)-1,2,4-triazole-3-carboxamide (Ribavirin, RBV). EICAR was more active than RBV against CDV replication, while both molecules exhibited low selectivity indexes. A reversal of their antiviral activity was observed after addition of guanosine, suggesting their involvement in the inhibition of the inosine monophosphate dehydrogenase enzyme (IMPDH). RBV and EICAR had a time- and concentration-dependent anti-CDV activity, mainly displayed during the first 10 h post-infection. The involvement of the inhibition of the viral RNA polymerase RNA dependent (vRdRp) is discussed, as well as the role of CDV as a model to study more potent and selective antiviral molecules active against other paramyxoviruses.